|
⚲
|
| Keyboard |
| Soleus Capital Management LP
✚
|
|
|---|---|
| CRD # | 294459 |
| SEC # | 801-118942 |
| CIK # | 0001786724, 0001802630, 0001812276 |
| AUM | 3,663.3 M (2026-04-27) |
| Employees | 23 (52% Investors, 0% Brokers) |
| Phone | 475-208-3178 |
| Address | 100 Field Point Road Greenwich, CT 06830 |
| Source | [IAPD] [EDGAR] [Website] [LinkedIn] |
| Total AUM ($B) |
|---|
| Sector | Form 13F Holdings | Value ($B) | |
|---|---|---|---|
| Krystal Biotech Inc | 0.3 | ||
| Celcuity Inc | 0.1 | ||
| Manhattan Pharmaceuticals Inc | 0.1 | ||
| Insulet Corp | 0.1 | ||
| Novocure Ltd | 0.1 | ||
| United Therapeutics Corp | 0.1 | ||
| Praxis Precision Medicines Inc | 0.1 | ||
| Aastrom Biosciences Inc | 0.1 | ||
| Alkermes PLC | 0.1 | ||
| Biosante Pharmaceuticals Inc | 0.1 | ||
| View All | |||
| Holdings by Sector ($B) |
|---|
| Type | Form D Funds | Date | Sold | AUM |
|---|---|---|---|---|
| PE | SCOF SPV I LP | [2026-03-31] | 34.4 M | 33.7 M |
| Filed 2025-09-15 (D/A) · Exemption 506(b) · Remaining Indefinite · Duration One year or less · Revenue Decline to Disclose | ||||
| PE | SCOF AIV LP | 2025-03-28 | 20.6 M | |
| PE | SCOF Blocker AIV LP | 2025-03-28 | 73.0 M | |
| PE | SCOF Blocker II LLC | 2025-03-28 | 2.5 M | |
| PE | SCOF Blocker LLC | 2025-03-28 | 2.2 M | |
| PE | Soleus Credit Opportunities Fund I LP | [2025-03-28] | 144.2 M | 155.1 M |
| Filed 2025-09-15 (D/A) · Exemption 506(b) · Remaining Indefinite · Duration More than one year · Revenue Decline to Disclose | ||||
| PE | Soleus Credit Opportunities Offshore Fund I LP | [2025-03-28] | 29.2 M | |
| Filed 2025-09-15 (D/A) · Exemption 3(c)(7), 506(b), 3(c) · Remaining Indefinite · Duration More than one year · Revenue Decline to Disclose | ||||
| PE | Soleus Private Equity Fund III LP | [2023-03-15] | 218.0 M | 309.4 M |
| Offered $218,000,000 · Filed 2024-02-27 (D/A) · Exemption 3(c)(7), 506(b), 3(c) · Duration One year or less · Commission $185,853 · Revenue Decline to Disclose | ||||
| PE | Soleus Private Equity Fund II LP | [2022-03-07] | 136.8 M | 132.5 M |
| Offered $175,000,000 · Filed 2021-02-04 (D) · Exemption 506(b), 3(c)(7) · Remaining $38,250,000 · Duration More than one year · Revenue Decline to Disclose | ||||
| PE | Soleus BA SPV LLC | [2021-03-25] | 8.3 M | 0.1 M |
| Offered $8,342,000 · Filed 2022-02-23 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $15,000 · Duration One year or less · Revenue Decline to Disclose | ||||
| View All | ||||
| AUM Breakdown | Accounts | AUM ($B) |
|---|---|---|
| By Client Type | ||
| (a) Individuals (other than high net worth individuals) | 0 | 0.0 |
| (b) Individuals (high net worth individuals) | 0 | 0.0 |
| (c) Banking or thrift institutions | 0 | 0.0 |
| (d) Investment companies | 0 | 0.0 |
| (e) Business development companies | 0 | 0.0 |
| (f) Pooled investment vehicles | 14 | 3.7 |
| (g) Pension and profit sharing plans | 0 | 0.0 |
| (h) Charitable organizations | 0 | 0.0 |
| (i) State or municipal government entities | 0 | 0.0 |
| (j) Other investment advisers | 0 | 0.0 |
| (k) Insurance companies | 0 | 0.0 |
| (l) Sovereign wealth funds and foreign official institutions | 0 | 0.0 |
| (m) Corporations or other businesses not listed above | 0 | 0.0 |
| (n) Other | 0 | 0.0 |
| Total | 14 | 3.7 |
| By Discretionary | ||
| Discretionary | 14 | 3.7 |
| Non-Discretionary | 0 | 0.0 |
| Total | 14 | 3.7 |
| By Non-United States Persons | ||
| Non-United States Persons | 1.5 | |
| United States Persons | 2.2 | |
| Total | 14 | 3.7 |
| Form D Directors | Role | # Filings | # Firms | 2011 - 2026 |
|---|---|---|---|---|
| Steven Musumeci | Executive Officer | 22 | 5 | |
| Guy Levy | Executive Officer, Promoter | 12 | 2 | |
| Soleus Capital Management LP | Executive Officer, Promoter | 11 | 2 | |
| Soleus Private Equity GP I LLC | Executive Officer | 3 | 2 | |
| Soleus Credit GP I LLC | Executive Officer | 3 | 1 | |
| Soleus Capital LLC | Executive Officer | 2 | 1 | |
| Soleus Private Equity GP II LLC | Executive Officer | 1 | 1 | |
| Soleus Private Equity GP III LLC | Executive Officer | 1 | 1 |
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 4 | [0001786724] | |
| SC 13G | [0001786724] | |
| 13F-HR | [0001802630] | |
| 3 | [0001802630] | |
| 4 | [0001802630] | |
| 4 | [0001812276] |
| Form 13D/13G Filer | Form 13D/13G Subject | Filed |
|---|---|---|
| Soleus Capital LLC | Dariohealth Corp | [2020-07-31] |
| Soleus Capital LLC | ESSA Pharma Inc | [2019-08-28] |
| Firm Profile (Form ADV) | |
|---|---|
| Serves | Institutional |
| Fund Types | Hedge Fund, Private Equity |
| LEI | 549300QV6CWYRN1C1A8 |
| Insider Transaction (Form 3/4/5) | Date | Action | Shares | Price | Value ($) |
|---|---|---|---|---|---|
|
Lyra Therapeutics Inc LYRA
Common Stock
|
2020-05-05 | Sell | 16,909 | $16.00 | 270,544 |
|
Lyra Therapeutics Inc LYRA
Common Stock
|
2020-05-05 | Buy | 155,000 | $16.00 | 2,480,000 |
|
Lyra Therapeutics Inc LYRA
Common Stock
|
2020-05-05 | Conversion | 338,330 | $0.00 | |
|
Lyra Therapeutics Inc LYRA
Common Stock
|
2020-05-05 | Conversion | 104,608 | $0.00 | |
|
Lyra Therapeutics Inc LYRA
Common Stock
|
2020-05-05 | Option exercise | 31,382 | $8.63 | 270,827 |
|
Lyra Therapeutics Inc LYRA
Series B Convertible Preferred Stock · derivative
|
2020-05-05 | Conversion | 11,666,666 | $0.00 | |
|
Lyra Therapeutics Inc LYRA
Common Stock Warrant · derivative
|
2020-05-05 | Option exercise | 31,382 | $0.00 | |
|
Lyra Therapeutics Inc LYRA
Series C Convertible Preferred Stock · derivative
|
2020-05-05 | Conversion | 3,607,224 | $0.00 |
| Comparable Firms | State | AUM |
|---|---|---|
|
Vector Capital Management LP
✚
|
CA | 3,751.0 M |
|
Anchorage Capital Group LLC
✚
|
NY | 3,707.6 M |
|
Resource Capital Investment Corporation
✚
|
CA | 3,706.7 M |
|
Boussard & Gavaudan Investment Management LLP
✚
|
3,679.1 M | |
|
Victory Park Capital Advisors LLC
✚
|
IL | 3,647.8 M |
|
First Sentier Investors Australia Infrastructure Managers PTY
✚
|
3,638.1 M | |
|
Axar Capital Management LP
✚
|
NY | 3,598.9 M |
|
MPM Asset Management LLC
✚
|
MA | 3,558.1 M |
|
Sycamore Tree Capital Partners LP
✚
|
TX | 3,539.6 M |
|
Deer Park Road Management Company LP
✚
|
CO | 3,515.8 M |